Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Keymed Biosciences, Inc. ( (HK:2162) ) just unveiled an announcement.
Keymed Biosciences Inc. has completed a placing and subscription of shares, raising approximately HK$853.77 million in net proceeds. The funds will be allocated to research and development, commercialization efforts, capital expenditure for manufacturing and R&D facilities, and general corporate purposes. This financial maneuver is expected to bolster the company’s operational capabilities and enhance its market position in the biotechnology sector.
The most recent analyst rating on (HK:2162) stock is a Buy with a HK$60.93 price target. To see the full list of analyst forecasts on Keymed Biosciences, Inc. stock, see the HK:2162 Stock Forecast page.
More about Keymed Biosciences, Inc.
Keymed Biosciences Inc. is a company incorporated in the Cayman Islands, focusing on the biotechnology industry. The company is involved in research and development, as well as the commercialization of pharmaceutical products, with a particular emphasis on innovative therapies.
Average Trading Volume: 3,387,390
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$11.69B
For an in-depth examination of 2162 stock, go to TipRanks’ Overview page.